Rimonabant for overweight or obesity

Area of Science:

• Pharmacology
• Obesity Research
• Clinical Trials

Background:

• Rising global obesity rates necessitate effective weight management strategies.
• Rimonabant, a cannabinoid-1 receptor antagonist, has been explored for weight reduction.
• Phase III trials are evaluating rimonabant for long-term efficacy and safety in obese individuals.

Purpose of the Study:

• To assess the efficacy and safety of rimonabant for weight loss in overweight and obese adults.
• To compare the effects of different rimonabant dosages against placebo.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches (MEDLINE, EMBASE, Cochrane Library, LILACS).
• Inclusion criteria: RCTs comparing rimonabant with placebo or other weight loss interventions in adults.
• Primary outcomes: weight loss, morbidity, and adverse events; data collected and analyzed by two independent reviewers.

Main Results:

• Rimonabant 20 mg yielded a 4.9 kg greater weight reduction compared to placebo after one year, alongside improvements in waist circumference and lipid profiles.
• Rimonabant 5 mg showed a less significant weight reduction (1.3 kg greater than placebo) with no notable effects on lipids or blood pressure.
• The 20 mg dose was associated with significantly more adverse events (nervous system, psychiatric, gastrointestinal); attrition rates were high (~40%).

Conclusions:

• Rimonabant 20 mg offers modest weight loss (approx. 5%) but carries a higher risk of adverse effects.
• Potential benefits of even modest weight loss should be weighed against safety concerns.
• Further high-quality, longer-term studies are required to establish definitive recommendations for rimonabant in obesity management.